Artemis Strategic Investment Corporation Class A ARTE 深 滬
已收盤 11-03 16:00:00 美东时间
10.735
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 10.735
- 總市值 7668.33万
- 52周最高 11.74
- 市盈率 靜 77.62
- 換手率 0.00%
- 52周最低 9.975
- 委 比 0.00%
- 總股本 714.33万
- 歷史最高 11.74
- 量 比 0
- 振 幅 0.00%
- 歷史最低 9.70
- 每 手 1
- 風險率 0.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Limble Recognizes Thirteen Maintenance Heroes at Industry Summit
Unsung heroes of maintenance recognized at community gathering, highlighting co...
09-04 21:01
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
Artelo Biosciences, a clinical-stage pharmaceutical company, has priced its public offering of 640,924 shares of common stock at $4.40 per share and pre-funded warrants for up to 40,894 shares at $4.399 per warrant. The offering is expected to raise approximately $3.0 million in gross proceeds. Underwriters have a 45-day option to purchase an additional 102,272 shares. The offering is expected to close on September 5, 2025, subject to customary c...
09-04 12:37
Artelo Biosciences Announces Proposed Underwritten Public Offering
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on developing therapeutics targeting lipid-signaling pathways for conditions like cancer, pain, and dermatologic diseases, has announced the commencement of an underwritten public offering of its common stock and/or pre-funded warrants. The offering is subject to market conditions, and there is no assurance of completion, size, or terms. R.F. Lafferty & Co., ...
09-03 20:35
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
Artelo Biosciences announced interim results from its Phase 2 CAReS trial for ART27.13, showing significant improvements in weight, lean body mass, and activity in cancer patients with anorexia-cachexia syndrome (CACS). Patients on ART27.13 gained an average of 6.38% body weight vs. a 5.42% loss on placebo. The drug was well-tolerated with mild to moderate side effects. These results support further development and potential partnerships for ART2...
09-03 12:45
NextEra Energy Announces Settlement Rate for Corporate Units Issued in September 2022
JUNO BEACH, Fla., Aug. 28, 2025 /PRNewswire/ -- NextEra Energy, Inc. (NYSE: NEE...
08-28 19:30
H.I.G. Infrastructure Investiert in Den Finnischen Anbieter Für Kreislaufwirtschaft Fluo Group
LONDON, 20. August 2025 /PRNewswire/ -- H.I.G. Capital („H.I.G."), eine führen...
08-21 02:05
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
Artelo Biosciences entered into a PIPE for $9.475 million to support its SOL treasury strategy, becoming the first publicly traded pharma company to adopt SOL as a reserve asset. Lead investor Bartosz Lipiński will serve as a technical partner through CUBE, which secures storage and staking for Artelo's digital assets. The company aims to leverage Solana's scalability and decentralized infrastructure for long-term growth and enhanced shareholder ...
08-04 11:30
SciBase Announces Outcome in Directed Share Issue
STOCKHOLM, Aug. 1, 2025 /PRNewswire/ -- On 16 June 2025, SciBase Holding AB (pu...
08-01 15:40
增长11%！阿斯利康2025H1财报：营收280亿美元，Enhertu大卖22.89亿美元
（来源：抗体圈） 7月29日，跨国药企巨头阿斯利康（AstraZeneca）发布2025年上半年财报，交出一份超预期的成绩单：总营收达280.45亿美元（按固定...
07-31 09:23
Fortune Gibt Die Fortune Global 500-Liste Für 2025 Bekannt
Walmart ist zum 12. Mal in Folge die Nr. 1 Die USA bleiben mit den meisten Unt...
07-30 04:15
